-
Mashup Score: 1
Alicia Morgans and Cora Sternberg discuss the MAGNITUDE phase 3 trial which was pragmatically designed to test the benefit of the combination of niraparib + abiraterone acetate/prednisone for metastatic castration-resistant prostate cancer (mCRPC) in patients prospectively identified with and without alterations in genes associated with HRR using both tissue and blood-based approaches. Dr….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0A Pre-Specified Gene-by-Gene Analysis of Primary and Secondary Endpoints in the MAGNITUDE Clinical Trial - Shahneen Sandhu - 1 year(s) ago
Join Shahneen Sandhu and Alicia Morgans as they discuss the MAGNITUDE trial and the pre-specified gene-by-gene analysis that Dr Sandhu presented at ASCO 2022. Dr. Sandhu kicks off the conversation with a recap of the MAGNITUDE trial. She then explains how this follow-up study was a pre-specified analysis that looked at the primary endpoints and all the secondary endpoints in patients with at…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
A pre-specified gene-by-gene analysis of primary and secondary endpoints in the #MAGNITUDE clinical trial. @SandhuShahneen @PeterMacCC joins @CaPsurvivorship @DanaFarber in this conversation on UroToday > https://t.co/F1OoF6AAgk https://t.co/GB6Hd7PXKR
-
-
Mashup Score: 0A Pre-Specified Gene-by-Gene Analysis of Primary and Secondary Endpoints in the MAGNITUDE Clinical Trial - Shahneen Sandhu - 1 year(s) ago
Join Shahneen Sandhu and Alicia Morgans as they discuss the MAGNITUDE trial and the pre-specified gene-by-gene analysis that Dr Sandhu presented at ASCO 2022. Dr. Sandhu kicks off the conversation with a recap of the MAGNITUDE trial. She then explains how this follow-up study was a pre-specified analysis that looked at the primary endpoints and all the secondary endpoints in patients with at…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
A pre-specified gene-by-gene analysis of primary and secondary endpoints in the #MAGNITUDE clinical trial. @SandhuShahneen @PeterMacCC joins @CaPsurvivorship @DanaFarber in this conversation on UroToday > https://t.co/F1OoF6AAgk https://t.co/uRrfd0wudU
-
-
Mashup Score: 1A Pre-Specified Gene-by-Gene Analysis of Primary and Secondary Endpoints in the MAGNITUDE Clinical Trial - Shahneen Sandhu - 2 year(s) ago
Join Shahneen Sandhu and Alicia Morgans as they discuss the MAGNITUDE trial and the pre-specified gene-by-gene analysis that Dr Sandhu presented at ASCO 2022. Dr. Sandhu kicks off the conversation with a recap of the MAGNITUDE trial. She then explains how this follow-up study was a pre-specified analysis that looked at the primary endpoints and all the secondary endpoints in patients with at…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
A pre-specified gene-by-gene analysis of primary and secondary endpoints in the #MAGNITUDE clinical trial. @SandhuShahneen @PeterMacCC joins @CaPsurvivorship @DanaFarber in this conversation on UroToday > https://t.co/F1OoF6AAgk https://t.co/uCce7gWLpI
-
-
Mashup Score: 4The Use of PARP Inhibitors in Castrate-Resistant Prostate Cancer - Elena Castro & Joaquin Mateo - 2 year(s) ago
Elena Castro and Joaquin Mateo join Alicia Morgans in a conversation on data related to genetic testing, PARP inhibitors, and the data we saw come out of GU ASCO with the PROpel and MAGNITUDE trials and they discuss how this data impacts the use of PARP inhibitors in castrate-resistant prostate cancer (CRPC). Drs. Castro, Mateo, and Morgans discuss this data in terms of next-generation…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
The use of PARP inhibitors in castrate-resistant #ProstateCancer. @Ecastromarcos & @quimmateo joins @CaPsurvivorship @DanaFarber to discuss, genetic testing, PARP inhibitors, and data from the #PROpel and #MAGNITUDE trials. #WatchNow > https://t.co/vkfqp3ekEH @APCCC_Lugano https://t.co/jGLLL1W7Mq
-
-
Mashup Score: 2PARPi Combination Therapy Use in Clinical Practice - Ready for Prime-Time? - Maha Hussain and Fred Saad - 2 year(s) ago
Drs Maha Hussain and Fred Saad join Dr Alicia Morgans in a conversation on PARP combination therapy in prostate cancer and the status of its use in clinical practice. In this context, the group discusses the PROpel and the MAGNITUDE studies data and how the data can be used in clinical practice. Biographies: Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
PARPi combination therapy use in clinical practice - Ready for prime-time? Maha Hussain @LurieCancer and Fred Saad @chumontreal join @CaPsurvivorship @DanaFarber in a conversation on the #PROpel and the #MAGNITUDE study data. #WatchNow > https://t.co/3SiEZnfZeO @APCCC_Lugano https://t.co/H0ZoT7jYqR
-
-
Mashup Score: 0The Use of PARP Inhibitors in Castrate-Resistant Prostate Cancer - Elena Castro & Joaquin Mateo - 2 year(s) ago
Elena Castro and Joaquin Mateo join Alicia Morgans in a conversation on data related to genetic testing, PARP inhibitors, and the data we saw come out of GU ASCO with the PROpel and MAGNITUDE trials and they discuss how this data impacts the use of PARP inhibitors in castrate-resistant prostate cancer (CRPC). Drs. Castro, Mateo, and Morgans discuss this data in terms of next-generation…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
The use of PARP inhibitors in castrate-resistant #ProstateCancer. @Ecastromarcos & @quimmateo joins @CaPsurvivorship @DanaFarber to discuss, genetic testing, PARP inhibitors, and data from the #PROpel and #MAGNITUDE trials. #WatchNow > https://t.co/vkfqp2WJg7 @APCCC_Lugano https://t.co/1nVY5yKgc1
-
-
Mashup Score: 0PARPi Combination Therapy Use in Clinical Practice - Ready for Prime-Time? - Maha Hussain and Fred Saad - 2 year(s) ago
Drs Maha Hussain and Fred Saad join Dr Alicia Morgans in a conversation on PARP combination therapy in prostate cancer and the status of its use in clinical practice. In this context, the group discusses the PROpel and the MAGNITUDE studies data and how the data can be used in clinical practice. Biographies: Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
PARPi combination therapy use in clinical practice - Ready for prime-time? Maha Hussain @LurieCancer and Fred Saad @chumontreal join @CaPsurvivorship @DanaFarber in a conversation on the #PROpel and the #MAGNITUDE study data. #WatchNow > https://t.co/3SiEZmYWcO @APCCC_Lugano https://t.co/zRCGKnwFC6
-
-
Mashup Score: 1The Use of PARP Inhibitors in Castrate-Resistant Prostate Cancer - Elena Castro & Joaquin Mateo - 2 year(s) ago
Elena Castro and Joaquin Mateo join Alicia Morgans in a conversation on data related to genetic testing, PARP inhibitors, and the data we saw come out of GU ASCO with the PROpel and MAGNITUDE trials and they discuss how this data impacts the use of PARP inhibitors in castrate-resistant prostate cancer (CRPC). Drs. Castro, Mateo, and Morgans discuss this data in terms of next-generation…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
The use of PARP inhibitors in castrate-resistant #ProstateCancer. @Ecastromarcos & @quimmateo joins @CaPsurvivorship @DanaFarber to discuss, genetic testing, PARP inhibitors, and data from the #PROpel and #MAGNITUDE trials. #WatchNow > https://t.co/vkfqp3ekEH @APCCC_Lugano https://t.co/uSpbY5ExsJ
-
-
Mashup Score: 4PARPi Combination Therapy Use in Clinical Practice - Ready for Prime-Time? - Maha Hussain and Fred Saad - 2 year(s) ago
Drs Maha Hussain and Fred Saad join Dr Alicia Morgans in a conversation on PARP combination therapy in prostate cancer and the status of its use in clinical practice. In this context, the group discusses the PROpel and the MAGNITUDE studies data and how the data can be used in clinical practice. Biographies: Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
PARPi combination therapy use in clinical practice - Ready for prime-time? Maha Hussain @LurieCancer and Fred Saad @chumontreal join @CaPsurvivorship @DanaFarber in a conversation on the #PROpel and the #MAGNITUDE study data. #WatchNow > https://t.co/3SiEZmYong @APCCC_Lugano https://t.co/mlg4tFjWec
-
Combination of niraparib and abiraterone acetate + prednisone radiographic PFS as a first-line therapy in patients with HRR gene-mutated #mCRPC. @cnsternberg @WCMEnglanderIPM joins @CaPsurvivorship discussing the phase 3 #MAGNITUDE on UroToday > https://t.co/ZLhoC5fMd1 https://t.co/MjgKzcEbNj